DARE Stock Analysis: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$2.09
0.07 (3.47%)
▲
5d:
+0.48%
30d:
+4.5%
90d:
+14.21%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DARE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: DARE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $2.09, which is considered slightly high relative to its 30-day fair value range of $1.97 to $2.12. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.1) compared to its historical average (3.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DARE is in a uptrend. Immediate support is located at $1.85, while resistance sits at $2.50. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: DARE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.67 (+362.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DARE is in a uptrend. Immediate support is located at $1.85, while resistance sits at $2.50. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: DARE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.67 (+362.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.97 -
$2.12
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 362.5% below Wall St target ($9.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$1.97 -
$2.12
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.85
Resistance Level
$2.50
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.10
Wall Street Target
$9.67
(+362.5%)
Revenue Growth (YoY)
499.6%
PE vs Historical
-4.1 vs 3.6
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 3:07 AM ET
Data refreshes hourly during market hours. Next update: 4:07 AM
Data refreshes hourly during market hours. Next update: 4:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
